SKCC's Gennadi Glinsky addresses predicting risk in cancer treatment outcome

-up a clinical trial to evaluate the utility of a genetic test measuring the expression profiles of the 11-gene signature as a prognostic and therapy outcome marker.

Gennadi Victor Glinsky, M.D., Ph.D.

Gennadi Victor Glinsky, M.D., Ph.D., is an associate professor at the Sidney Kimmel Cancer Center in San Diego. He is also a consultant for the National Institutes of Health and serves on the National Cancer Institute Review Panels.

Dr. Glinsky holds membership to numerous professional organizations such as the American Association for the Advancement of Science, the American Association for Cancer Research and the Metastasis Research Society. Dr. Glinsky serves as a reviewer for various journals including the Lancet, Journal of Clinical Investigation, Cancer Research, American Journal of Pathology and Oncogene.

Dr. Glinsky earned a doctor of medicine in internal medicine and general pathology. He later received his doctorate in experimental oncology and biochemistry from the Institute of Oncology Problems Academy of Sciences of Ukraine in Kiev.


Contact: Jay Jeffcoat
Sidney Kimmel Cancer Center

Page: 1 2

Related medicine news :

1. Asia-European collaboration addresses water management in Indonesia
2. New technology addresses female fertility preservation
3. New research addresses taboos around the impact of rheumatoid arthritis on patients sex lives
4. Friedman addresses UN-sponsored African workshop on E-Governance
5. New handbook addresses lesbian, gay, bisexual and transgender health issues
6. UK addresses funding gap created by US anti-abortion stance
7. New pediatrician workforce policy addresses growing challenges in health care
8. Child magazine editor addresses regions first annual womens and childrens health care conference
9. Why predicting the next influenza pandemic is difficult and how scientists can best prepare
10. Repeat bone mineral density scans do not appear helpful for predicting fractures in most older women
11. HIV measurement appears to be less reliable than thought in predicting loss of CD4 cells

Post Your Comments:
(Date:10/8/2015)... (PRWEB) , ... October 08, 2015 , ... Multicultural competencies ... Day, presented by Calvary Hospital. , The ninth annual event will take place from ... on Second Avenue at 34th Street in Manhattan. This location was chosen to conveniently ...
(Date:10/8/2015)... ... October 08, 2015 , ... In an increasingly complex healthcare ... to consistently deliver the highest quality of care, while exploring controversial issues impacting ... this year’s NASS meeting, the Spine division of Zimmer Biomet, a leading global ...
(Date:10/8/2015)... ... October 08, 2015 , ... Mirixa Corporation ... decade as the recognized leader in targeted patient care services, Mirixa remains dedicated ... community pharmacies available. Recent changes in the health care marketplace threaten to limit ...
(Date:10/8/2015)... White Plains, NY (PRWEB) , ... October 08, 2015 , ... ... comparison company, shows that popular, branded maintenance medications can be purchased at an 84% ... The greatest savings is 94% for the acid-blocking drug Nexium ($946.50 in the U.S. ...
(Date:10/8/2015)... ... 08, 2015 , ... Carpet One Floor & Home has just released their ... One Welcomes Your Support campaign has been raising funds to support organizations and researchers ... , Twenty-five percent of each sale will be donated to the Breast Cancer ...
Breaking Medicine News(10 mins):
(Date:10/8/2015)...  Clariant, a world leader in specialty chemicals, has announced ... Belen, New Mexico , has achieved ISO 15378:2011 ... canisters and packets and other container-closure systems . ... second Clariant site – the first in the ... standards, following only the Clariant manufacturing facility in Romorantin, ...
(Date:10/8/2015)... FRANCISCO , Oct. 8, 2015  Nektar Therapeutics ... the Company,s pain and oncology portfolio during an Investor ... - 3:30 p.m. Eastern Time in New ... carcinoma.  Details of the NKTR-214 Phase 1/2 clinical program ... CD122-biased immune-stimulatory cytokine designed to preferentially stimulate the production ...
(Date:10/8/2015)... -- Celtaxsys, a clinical stage drug development company focused on ... announced today the commencement of the US arm of ... compound, acebilustat, in patients with cystic fibrosis (CF). The ... the United States and European ... early 2016. This landmark clinical trial testing once-daily oral ...
Breaking Medicine Technology:
Cached News: